孟鲁司特钠治疗小儿过敏性紫癜的临床疗效及其安全性

Clinical efficacy and safety of montelukast in children with henoch-schonlein purpura

目的分析孟鲁司特钠治疗小儿过敏性紫癜的临床疗效及其安全性。方法回顾性分析我院收治的920例过敏性紫癜患儿的临床资料,随机分为A组和B组,各460例。B组患儿口服氯雷他定颗粒并肌肉注射西咪替丁进行治疗,A组患儿在B组患儿治疗方法基础上服用孟鲁司特钠药物进行治疗,在连续治疗2周后,比较两组患儿的治疗总有效率。结果 A组患儿治疗总有效率明显优于B组治疗总有效率(P0.05),A组患儿的皮肤紫癜消失时间、消化道病变消失时间、关节肿痛消失时间明显优于B组(P<0.05)。结论孟鲁司特钠治疗小儿过敏性紫癜疗效显著,能够促使小儿过敏性紫癜症状、关节肿痛消失时间以及消化道病变消失时间得以缩短,值得临床应用推广。

Objective To analyze the clinical efficacy and safety of montelukast in children with henoch-schonlein purpura. Methods The clinical data of 920 cases of children with allergic purpura in our hospital were retrospectively analyzed. All the children were divided into group A and group B, with 460 cases in each group. The group B received oral loratadine particles and cimetidine intramuscular injection, while group A were given montelukast sodium on the basis of group B. After two weeks of continuous treatment, the effective rates of the two groups were compared. Results The treatment effective rate of group A was significantly better than that of group B （P〈0.05）. The skin purpura disappearance time, gastrointestinal lesions disappearance time, joint swelling and pain disappearance time of group A were hetter than those of group B （P〈0.05）. Conclusion Montelukast sodium has significant effect in the treatment of children with henoeh-schonlein purpura. It can shorten the disappearance time of henoch-schonlein purpura symptoms, joint swelling and pain as well as gastrointestinal lesions. It is worthy of popularization in clinical application.